1. Antifungal Agents and Fungal Prophylaxis in the Neonate
- Author
-
Stephen D. Kicklighter
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Mortality rate ,Incidence (epidemiology) ,Retinopathy of prematurity ,medicine.disease ,biology.organism_classification ,Sepsis ,Intraventricular hemorrhage ,Internal medicine ,Amphotericin B ,Pediatrics, Perinatology and Child Health ,Medicine ,business ,Intensive care medicine ,Candida albicans ,Meningitis ,medicine.drug - Abstract
After completing this article, readers should be able to: 1. Delineate the third most common cause of late-onset sepsis in very low-birthweight infants. 2. Describe the primary predictors for successful treatment of potential fungal sepsis and culture-positive sepsis. 3. List the gold standard for antifungal therapy in the neonate. 4. Compare and contrast liposomal amphotericin B and amphotericin B and describe the neonates in whom liposomal amphotericin B should be used. 5. Describe the situation in which antifungal prophylaxis may be appropriate. Among the 6,956 very low-birthweight (VLBW) (
- Published
- 2002
- Full Text
- View/download PDF